Catheter Precision (NYSEAMERICAN:VTAK) Shares Up 6.8% – Still a Buy?

Catheter Precision, Inc. (NYSEAMERICAN:VTAK)’s share price shot up 6.8% during trading on Friday . The stock traded as high as $0.21 and last traded at $0.21. 879,451 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 5,109,958 shares. The stock had previously closed at $0.1966.

Catheter Precision Stock Up 6.8%

The firm has a market cap of $3.02 million, a PE ratio of -0.03 and a beta of -1.03. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.18 and a current ratio of 0.19. The firm’s 50-day moving average price is $0.43 and its two-hundred day moving average price is $0.87.

Catheter Precision (NYSEAMERICAN:VTAK) last posted its earnings results on Friday, August 14th. The company reported ($0.92) EPS for the quarter, beating analysts’ consensus estimates of ($19.00) by $18.08. Catheter Precision had a negative net margin of 656.03% and a negative return on equity of 37.53%. The firm had revenue of $1.02 million for the quarter, compared to the consensus estimate of $2.00 million.

Hedge Funds Weigh In On Catheter Precision

An institutional investor recently bought a new position in Catheter Precision stock. Millennium Management LLC bought a new position in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned approximately 2.08% of Catheter Precision as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 20.34% of the company’s stock.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.